Jean C Beckham1, Kelsie A Adkisson2, Jeffrey Hertzberg2, Nathan A Kimbrel3, Alan J Budney4, Robert S Stephens5, Scott D Moore3, Patrick S Calhoun6. 1. Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27705, USA; Veterans Affairs Mid-Atlantic Region Mental Illness Research, Education, and Clinical Center, Durham, NC 27705, USA. Electronic address: jean.beckham@va.gov. 2. Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27705, USA; Durham Veterans Affairs Medical Center, Durham, NC, 27705, USA. 3. Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27705, USA; Veterans Affairs Mid-Atlantic Region Mental Illness Research, Education, and Clinical Center, Durham, NC 27705, USA. 4. Geisel School of Medicine at Dartmouth, Center for Technology and Behavioral Health, Lebanon, NH 03766, USA. 5. Virginia Polytechnic Institute and State University, Department of Psychology, Blacksburg, VA 24061, USA. 6. Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27705, USA; Veterans Affairs Mid-Atlantic Region Mental Illness Research, Education, and Clinical Center, Durham, NC 27705, USA; Veterans Affairs Center for Health Services Research in Primary Care, Durham, NC, 27705, USA.
Abstract
INTRODUCTION: Cannabis is the most widely used illicit drug in the U.S. with 19.8 million current users. Population-based data indicate that almost all cannabis users (90%) have a lifetime history of tobacco smoking and the majority (74%) currently smoke tobacco. Among cannabis users, smoking tobacco is associated with increased frequency of cannabis use, increased morbidity, and poorer cannabis cessation outcomes. There is a lack of research, however, focused on addressing cessation of both substances simultaneously. The purpose of the current pilot study was to evaluate the feasibility and acceptability of a multi-component tobacco/cannabis abstinence treatment. METHODS: Five participants completed Abstinence Reinforcement Therapy, an intervention that included five sessions of cognitive-behavioral telephone counseling for tobacco/cannabis, pharmacotherapy for smoking cessation, and five weeks of mobile contingency management to remain abstinent from tobacco and cannabis. RESULTS: Feasibility of recruitment, retention and treatment completion was high. Satisfaction with the treatment was also high. CONCLUSION: Results support the feasibility and acceptability of this approach with dual cannabis and tobacco users and suggest that further research examining the efficacy of this approach is warranted. Published by Elsevier Ltd.
INTRODUCTION: Cannabis is the most widely used illicit drug in the U.S. with 19.8 million current users. Population-based data indicate that almost all cannabis users (90%) have a lifetime history of tobacco smoking and the majority (74%) currently smoke tobacco. Among cannabis users, smoking tobacco is associated with increased frequency of cannabis use, increased morbidity, and poorer cannabis cessation outcomes. There is a lack of research, however, focused on addressing cessation of both substances simultaneously. The purpose of the current pilot study was to evaluate the feasibility and acceptability of a multi-component tobacco/cannabis abstinence treatment. METHODS: Five participants completed Abstinence Reinforcement Therapy, an intervention that included five sessions of cognitive-behavioral telephone counseling for tobacco/cannabis, pharmacotherapy for smoking cessation, and five weeks of mobile contingency management to remain abstinent from tobacco and cannabis. RESULTS: Feasibility of recruitment, retention and treatment completion was high. Satisfaction with the treatment was also high. CONCLUSION: Results support the feasibility and acceptability of this approach with dual cannabis and tobacco users and suggest that further research examining the efficacy of this approach is warranted. Published by Elsevier Ltd.
Entities:
Keywords:
Cannabis treatment; Comorbidity; Smoking cessation; Tobacco control
Authors: C W Lejuez; Jennifer P Read; Christopher W Kahler; Jerry B Richards; Susan E Ramsey; Gregory L Stuart; David R Strong; Richard A Brown Journal: J Exp Psychol Appl Date: 2002-06
Authors: D Robin Taylor; David M Fergusson; Barry J Milne; L John Horwood; Terrie E Moffitt; Malcolm R Sears; Richie Poulton Journal: Addiction Date: 2002-08 Impact factor: 6.526
Authors: Kimber P Richter; Haroshena Kaur; Ken Resnicow; Niaman Nazir; Michael C Mosier; Jasjit S Ahluwalia Journal: Subst Abus Date: 2004-06 Impact factor: 3.716
Authors: Miles McFall; Andrew J Saxon; Carol A Malte; Bruce Chow; Sara Bailey; Dewleen G Baker; Jean C Beckham; Kathy D Boardman; Timothy P Carmody; Anne M Joseph; Mark W Smith; Mei-Chiung Shih; Ying Lu; Mark Holodniy; Philip W Lavori Journal: JAMA Date: 2010-12-08 Impact factor: 56.272
Authors: Sarah H Heil; Stephen T Higgins; Ira M Bernstein; Laura J Solomon; Randall E Rogers; Colleen S Thomas; Gary J Badger; Mary Ellen Lynch Journal: Addiction Date: 2008-06 Impact factor: 6.526
Authors: Dustin C Lee; Alan J Budney; Mary F Brunette; John R Hughes; Jean-Francois Etter; Catherine Stanger Journal: Drug Alcohol Depend Date: 2015-08-10 Impact factor: 4.492
Authors: Erin A McClure; Rachel L Tomko; Claudia A Salazar; Saima A Akbar; Lindsay M Squeglia; Evan Herrmann; Matthew J Carpenter; Erica N Peters Journal: Exp Clin Psychopharmacol Date: 2018-12-17 Impact factor: 3.157
Authors: Saima A Akbar; Rachel L Tomko; Claudia A Salazar; Lindsay M Squeglia; Erin A McClure Journal: Addict Behav Date: 2018-11-27 Impact factor: 3.913
Authors: Stephanie Carreiro; Mark Newcomb; Rebecca Leach; Simon Ostrowski; Edwin D Boudreaux; Daniel Amante Journal: Drug Alcohol Depend Date: 2020-08-02 Impact factor: 4.492
Authors: Rachel L Tomko; Kevin M Gray; Marilyn A Huestis; Lindsay M Squeglia; Nathaniel L Baker; Erin A McClure Journal: Curr Addict Rep Date: 2019-11-19
Authors: August F Holtyn; Forrest Toegel; Matthew D Novak; Jeannie-Marie Leoutsakos; Michael Fingerhood; Kenneth Silverman Journal: Drug Alcohol Depend Date: 2021-05-27 Impact factor: 4.852